1.	Study to Evaluate Erlotinib With or Without SNDX-275 in the Treatment of Patients With Advanced NSCLC Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SNDX-275-0401, NCT00602030
2.	MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000540608, U01CA070095, P30CA006973, JHOC-J06114, J06114, 7605, NA_00006989, NCT00462605
3.	Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SNDX-275-0301, NCT00676663
4.	A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib Phase: Phase II Type: Treatment Status: Completed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: SNDX-275-0403, NCT00750698
5.	A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing Phase: Phase II Type: Treatment Status: Completed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: SNDX-275-0303, NCT00828854
6.	A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SNDX-275-0501, NCT00866333
7.	Phase II Study of Azacitidine and Entinostat in Patients With Metastatic Colorectal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-MC084B, MC084B, 8341, NCT01105377
8.	MS-275 in Treating Patients With Hematologic Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068574, J0253, U01CA069854, P30CA006973, JHOC-J0253, MSGCC-0050, NCI-2791, NCT00015925
9.	Phase I Study of MS-275 and Isotretinoin in Patients With Metastatic, Progressive, Refractory, or Unresectable Solid Tumors or Lymphomas Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: JHOC-J0438, 6798, NCI-6798, JHOC-04060103, NCT00098891
10.	MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000405841, J0443, U01CA070095, P30CA006973, JHOC-J0443, NCI-6591, JHOC-04061109, 6591, NCT00101179
11.	Phase I Study of Entinostat and Sorafenib Tosylate in Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI Protocol IDs: RPCI-I-165409, I-165409, 8272, NCT01159301
12.	MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, NIH WGMCC Protocol IDs: 010124, 01-C-0124, NCI-2792, CDR0000068615, NCI-01-C-0124, 2792, NCT00020579